Amgen has secured a recommendation for its new cholesterol drug Repatha (evolocumab) from NICE, giving it a major advantage on Sanofi/Regeneron's rival Praluent (alirocumab).

Amgen is cutting the US price of its cholesterol drug Repatha by 60%, following a similar decision by rivals Sanofi and Regeneron earlier this year. Repatha (evolocumab) will now be sold at $5,850 ...